Together is a new resource for anyone affected by pediatric cancer - patients and their parents, family members, and friends.Learn More
Often used for:
Blinatumomab is a type of immunotherapy called a bispecific T-cell engager (BITE) monoclonal antibody. This medicine works by causing T cells to target a protein called CD19 found on some types of leukemia cells. Blinatumomab is considered a targeted therapy because the medicine is specific to certain cell features and “targets” those cells.
A serious condition called cytokine release syndrome (CRS) can occur while taking this drug. This usually occurs within the first few days of receiving the medicine, and patients will be monitored closely during this time.
Patients will have regular blood draws to check blood counts and monitor liver function.
Given as a liquid into a vein by IV
Not all patients who take blinatumomab will experience these side effects. Common side effects are in bold, but there may be others. Please report all suspected side effects to your doctor or pharmacist.
Be sure to discuss these and other recommendations with your doctor or pharmacist.